The consensus of experts in China in diagnosing and treating BM of lung cancer suggests asymptomatic BM patients should be initiated systemic treatment (ALK-positive patients receive first-line crizotinib), and patients with symptomatic BM and stable extracranial lesions should be actively treated locally. This evidence concerns the gene ALK and lung carcinoma.